Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale)

Vito Lorusso, M. Spada, M. Giampaglia, A. Misino, R. Calabrese, A. Latorre, G. Monticelli, M. Guida, D. Sambiasi, G. Colucci

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Vinorelbine i.v. and capecitabine are two of the most effective single agents in previously treated advanced breast cancer (ABC). A number of studies have been reported with the combination of these agents. Actually, the availability of oral formulation for vinorelbine allows a full oral combination of the two agents. The aim of this study was to evaluate the activity and toxicity of this novel combination. Patients and methods: Thirty-eight advanced breast cancer patients refractory to anthracyclines and taxanes were included in this study. Treatment consisted of vinorelbine 60 mg/m 2 (days 1 + 8), and capecitabine 2000 mg/m2 (days 2-7 and 9-16) every 3 weeks. Results: A total of 228 courses were given with a mean of three cycles/patient (range 1-12). Five patients (13.1%) had no toxicity at all. Hematologic side-effects were: neutropenia grade 2-3 in seven patients (18.9%) and grade 4 in one patient (2.7%), anemia grade 1 in 11 patients (29.7%), grade 2-3 in five patients (13.5%), thrombocytopenia grade 1 in six patients (16.2%) and grade 3 in one patient (2.7%). Non-hematologic side-effects were: fatigue grade 1 in five patients (13.5%), hand-foot syndrome grade 1 in two patients (5.4%) and grade 2 in two patients (5.4%), nausea/vomiting grade 1 in two patients (5.4%), grade 2 in three patients (8.1%) and grade 3 in one patient (2.7%), constipation grade 1 in two patients (5.4%), peripheral neurotoxicity grade 1 in three patients (8.1%) and grade 2 in one patient (2.7%), gastric pain grade 1 in two patients (5.4%), stomatitis grade 1 in three patients (8.1%) and grade 2 in one patient (2.7%). Out of 38 patients assessable, we observed two (5.4%) CR, 13 (34 %) PR, 14 (37.8%) SD and nine (26.3%) PD. The median time to progression was 4.5 months (range 1-18 months), the median response duration was 7 months (range 2-18 months) and the median survival duration was 10 months (range 2-26+). Conclusions: The oral vincap should be considered as an alternative to single agent capecitabine or vinorelbine in ABC refractory to antra-taxane combination.

Original languageEnglish
JournalAnnals of Oncology
Volume17
Issue numberSUPPL. 7
DOIs
Publication statusPublished - Jun 2006

Fingerprint

Breast Neoplasms
Capecitabine
vinorelbine
Hand-Foot Syndrome
Taxoids
Stomatitis
Anthracyclines
Constipation
Neutropenia
Nausea
Vomiting
Fatigue
Anemia
Stomach

Keywords

  • Breast cancer
  • Capecitabine
  • Oral chemotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale). / Lorusso, Vito; Spada, M.; Giampaglia, M.; Misino, A.; Calabrese, R.; Latorre, A.; Monticelli, G.; Guida, M.; Sambiasi, D.; Colucci, G.

In: Annals of Oncology, Vol. 17, No. SUPPL. 7, 06.2006.

Research output: Contribution to journalArticle

@article{5df86f5e0ee141bebd21035de5d08e0e,
title = "Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale)",
abstract = "Background: Vinorelbine i.v. and capecitabine are two of the most effective single agents in previously treated advanced breast cancer (ABC). A number of studies have been reported with the combination of these agents. Actually, the availability of oral formulation for vinorelbine allows a full oral combination of the two agents. The aim of this study was to evaluate the activity and toxicity of this novel combination. Patients and methods: Thirty-eight advanced breast cancer patients refractory to anthracyclines and taxanes were included in this study. Treatment consisted of vinorelbine 60 mg/m 2 (days 1 + 8), and capecitabine 2000 mg/m2 (days 2-7 and 9-16) every 3 weeks. Results: A total of 228 courses were given with a mean of three cycles/patient (range 1-12). Five patients (13.1{\%}) had no toxicity at all. Hematologic side-effects were: neutropenia grade 2-3 in seven patients (18.9{\%}) and grade 4 in one patient (2.7{\%}), anemia grade 1 in 11 patients (29.7{\%}), grade 2-3 in five patients (13.5{\%}), thrombocytopenia grade 1 in six patients (16.2{\%}) and grade 3 in one patient (2.7{\%}). Non-hematologic side-effects were: fatigue grade 1 in five patients (13.5{\%}), hand-foot syndrome grade 1 in two patients (5.4{\%}) and grade 2 in two patients (5.4{\%}), nausea/vomiting grade 1 in two patients (5.4{\%}), grade 2 in three patients (8.1{\%}) and grade 3 in one patient (2.7{\%}), constipation grade 1 in two patients (5.4{\%}), peripheral neurotoxicity grade 1 in three patients (8.1{\%}) and grade 2 in one patient (2.7{\%}), gastric pain grade 1 in two patients (5.4{\%}), stomatitis grade 1 in three patients (8.1{\%}) and grade 2 in one patient (2.7{\%}). Out of 38 patients assessable, we observed two (5.4{\%}) CR, 13 (34 {\%}) PR, 14 (37.8{\%}) SD and nine (26.3{\%}) PD. The median time to progression was 4.5 months (range 1-18 months), the median response duration was 7 months (range 2-18 months) and the median survival duration was 10 months (range 2-26+). Conclusions: The oral vincap should be considered as an alternative to single agent capecitabine or vinorelbine in ABC refractory to antra-taxane combination.",
keywords = "Breast cancer, Capecitabine, Oral chemotherapy, Vinorelbine",
author = "Vito Lorusso and M. Spada and M. Giampaglia and A. Misino and R. Calabrese and A. Latorre and G. Monticelli and M. Guida and D. Sambiasi and G. Colucci",
year = "2006",
month = "6",
doi = "10.1093/annonc/mdl942",
language = "English",
volume = "17",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 7",

}

TY - JOUR

T1 - Oral vinorelbine plus capecitabine (oral vincap) combination in patients with advanced breast cancer (ABC). A phase II study of the GOIM (Gruppo Oncologico dell'Italia Meridionale)

AU - Lorusso, Vito

AU - Spada, M.

AU - Giampaglia, M.

AU - Misino, A.

AU - Calabrese, R.

AU - Latorre, A.

AU - Monticelli, G.

AU - Guida, M.

AU - Sambiasi, D.

AU - Colucci, G.

PY - 2006/6

Y1 - 2006/6

N2 - Background: Vinorelbine i.v. and capecitabine are two of the most effective single agents in previously treated advanced breast cancer (ABC). A number of studies have been reported with the combination of these agents. Actually, the availability of oral formulation for vinorelbine allows a full oral combination of the two agents. The aim of this study was to evaluate the activity and toxicity of this novel combination. Patients and methods: Thirty-eight advanced breast cancer patients refractory to anthracyclines and taxanes were included in this study. Treatment consisted of vinorelbine 60 mg/m 2 (days 1 + 8), and capecitabine 2000 mg/m2 (days 2-7 and 9-16) every 3 weeks. Results: A total of 228 courses were given with a mean of three cycles/patient (range 1-12). Five patients (13.1%) had no toxicity at all. Hematologic side-effects were: neutropenia grade 2-3 in seven patients (18.9%) and grade 4 in one patient (2.7%), anemia grade 1 in 11 patients (29.7%), grade 2-3 in five patients (13.5%), thrombocytopenia grade 1 in six patients (16.2%) and grade 3 in one patient (2.7%). Non-hematologic side-effects were: fatigue grade 1 in five patients (13.5%), hand-foot syndrome grade 1 in two patients (5.4%) and grade 2 in two patients (5.4%), nausea/vomiting grade 1 in two patients (5.4%), grade 2 in three patients (8.1%) and grade 3 in one patient (2.7%), constipation grade 1 in two patients (5.4%), peripheral neurotoxicity grade 1 in three patients (8.1%) and grade 2 in one patient (2.7%), gastric pain grade 1 in two patients (5.4%), stomatitis grade 1 in three patients (8.1%) and grade 2 in one patient (2.7%). Out of 38 patients assessable, we observed two (5.4%) CR, 13 (34 %) PR, 14 (37.8%) SD and nine (26.3%) PD. The median time to progression was 4.5 months (range 1-18 months), the median response duration was 7 months (range 2-18 months) and the median survival duration was 10 months (range 2-26+). Conclusions: The oral vincap should be considered as an alternative to single agent capecitabine or vinorelbine in ABC refractory to antra-taxane combination.

AB - Background: Vinorelbine i.v. and capecitabine are two of the most effective single agents in previously treated advanced breast cancer (ABC). A number of studies have been reported with the combination of these agents. Actually, the availability of oral formulation for vinorelbine allows a full oral combination of the two agents. The aim of this study was to evaluate the activity and toxicity of this novel combination. Patients and methods: Thirty-eight advanced breast cancer patients refractory to anthracyclines and taxanes were included in this study. Treatment consisted of vinorelbine 60 mg/m 2 (days 1 + 8), and capecitabine 2000 mg/m2 (days 2-7 and 9-16) every 3 weeks. Results: A total of 228 courses were given with a mean of three cycles/patient (range 1-12). Five patients (13.1%) had no toxicity at all. Hematologic side-effects were: neutropenia grade 2-3 in seven patients (18.9%) and grade 4 in one patient (2.7%), anemia grade 1 in 11 patients (29.7%), grade 2-3 in five patients (13.5%), thrombocytopenia grade 1 in six patients (16.2%) and grade 3 in one patient (2.7%). Non-hematologic side-effects were: fatigue grade 1 in five patients (13.5%), hand-foot syndrome grade 1 in two patients (5.4%) and grade 2 in two patients (5.4%), nausea/vomiting grade 1 in two patients (5.4%), grade 2 in three patients (8.1%) and grade 3 in one patient (2.7%), constipation grade 1 in two patients (5.4%), peripheral neurotoxicity grade 1 in three patients (8.1%) and grade 2 in one patient (2.7%), gastric pain grade 1 in two patients (5.4%), stomatitis grade 1 in three patients (8.1%) and grade 2 in one patient (2.7%). Out of 38 patients assessable, we observed two (5.4%) CR, 13 (34 %) PR, 14 (37.8%) SD and nine (26.3%) PD. The median time to progression was 4.5 months (range 1-18 months), the median response duration was 7 months (range 2-18 months) and the median survival duration was 10 months (range 2-26+). Conclusions: The oral vincap should be considered as an alternative to single agent capecitabine or vinorelbine in ABC refractory to antra-taxane combination.

KW - Breast cancer

KW - Capecitabine

KW - Oral chemotherapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=33745613545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745613545&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdl942

DO - 10.1093/annonc/mdl942

M3 - Article

C2 - 16760280

AN - SCOPUS:33745613545

VL - 17

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 7

ER -